LQDA — Liquidia Technologies Inc
NASDAQ · Healthcare · Biotechnology
$68.07
+$1.16 (+1.73%)
Liquidia Technologies Inc (LQDA) is a biotechnology company listed on NASDAQ. It is led by Roger A. Jeffs Ph.D., based in 419 Davis Drive, Morrisville, NC, United States, 27560, with about 170 employees. Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Latest reported LQDA revenue for 2025-09-30 was $54.3M. Net income was -$83.5M. Revenue was up 514.9% from 2025-06-30 to 2025-09-30. LQDA currently screens at market cap $1.04B.
Use this LQDA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the LQDA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the LQDA SEC filings page. Lician reads the product cache first so this HTML stays unique to Liquidia Technologies Inc even when a live quote feed is slow.
About Liquidia Technologies Inc
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
LQDA Key Statistics
Market Cap
$1.04B
Volume
801,233
Previous Close
$70.27
Day Range
$70.10 – $73.07
EPS
-$1.66
Revenue
$14.00M
Net Income
-$130.39M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-20.0%
Profit Margin
-931.7%
Employees
170
LQDA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $14.00M | $17.49M | $15.94M | $12.85M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$130.39M | -$78.50M | -$41.02M | -$34.58M |
| EPS (Diluted) | -$1.66 | -$1.21 | -$0.67 | -$0.70 |
Total Assets
$230.31M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$176.48M
Operating Cash Flow
-$93.42M
Free Cash Flow
$0.00
Liquidia Technologies Inc Company Information
- CEO & Director
- Roger A. Jeffs Ph.D.
- Headquarters
- 419 Davis Drive, Morrisville, NC, United States, 27560
- Website
- www.liquidia.com
- Phone
- 919 328 4400
- IPO / Founded
- 2018-07-26
- Sector
- Healthcare
- Industry
- Biotechnology